Reta (GLP-3) onderzoeksproduct
US$ 26.97
glp-1 drug updates Safety Check GLP-1 Antagonists Increase Plan Drug
Description
In response to the Icelandic Medicines Agencys alert regarding reports of suicidal thoughts and self-injury linked to the use of liraglutide and semaglutide, we undertook a comprehensive analysis to assess the risk of suicide/self-injury associated with various GLP-1RAs
Because the drugs slow down digestion, food can ferment in the stomach, leading to a build up of hydrogen sulfide
It takes time to get a firm grasp of the true risk profile of a drug
lecture fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Lifescan, Merck Sharp & Dohme, Novartis, Novo Nordisk, Roche Diabetes Care, and Sanofi
